AbbVie's 'Unjustified' Humira Settlements Divide Market, Claims Class Action
Executive Summary
First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.
You may also be interested in...
BI Bags Third Place For Humira Biosimilar in US With AbbVie Pact
Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.
Boehringer Settlement Jumps The Queue For Biosimilar Adalimumab
Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.
Second-Medical-Use Patents Pose Problems For Biosimilars
Patents for secondary indications of biologic reference drugs are causing headaches for companies developing biosimilar rivals.